About 995 results

ALLMedicine™ Prolactinoma Center

Research & Reviews  355 results

Macroprolactinoma with secondary resistance to dopamine agonists: a case report and rev...
Journal of Medical Case Reports; Tng EL, Teo AE et. al.

Mar 18th, 2023 - Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past four de...

Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagn...
Andrology Rudman Y, Duskin-Bitan H et. al.

Mar 11th, 2023 - Men harboring prolactinomas frequently suffer from central hypogonadism with secondary anemia. They present insidious and non-specific symptoms of hypogonadism, making it difficult to diagnose the disease and determine its duration. The result is ...

A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma:...
Clinical Neuropharmacology; Springer C, Rodgers R et. al.

Mar 7th, 2023 - Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time sh...

CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
Journal of Endocrinological Investigation; Wu N, Zhu D et. al.

Mar 1st, 2023 - Prolactinomas are one of the most common pituitary neuroendocrine tumors (PitNETs), accounting for approximately 50% of all pituitary tumors. Dopamine agonists are the main treatment for prolactinoma, but a small number of patients are still resis...

DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance...
Endocrine Tang H, Cheng Y et. al.

Jan 24th, 2023 - The dopamine agonists (DA) have been used widely to treat prolactinomas. However, it is difficult to predict whether the patient will be responsive to DA treatment. We aimed to investigate whether the in vivo expression of DRD2 based on 18F-fallyp...

see more →

Guidelines  1 results

Pituitary incidentaloma: an endocrine society clinical practice guideline.
The Journal of Clinical Endocrinology and Metabolism; Freda PU, Beckers AM et. al.

Apr 9th, 2011 - The aim was to formulate practice guidelines for endocrine evaluation and treatment of pituitary incidentalomas. Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails and one in-per...

see more →

Clinicaltrials.gov  18 results

Exercise Capacity and Physical Activity Level in Prolactinoma Patients

Nov 1st, 2022 - Prolactinoma is a pituitary adenoma caused by excessive prolactin secretion. More than 70% of patients are women. Many physiological conditions such as pregnancy, breastfeeding, breast stimulation, stress, exercise and sleep can also increase PRL ...

Multicenter Registry for Patients With Childhood.Onset Craniopharyngioma, Xanthogranuloma, Cysts of Rathke's Pouch, Meningioma, Pituitary Adenoma, Arachnoid Cysts

Mar 31st, 2022 - KRANIOPHARYNGEOM Registry 2019 will prospectively collect and descriptively analyse data on diagnostics, treatment, and follow-up of patients with craniopharyngioma. In continuation of preceding studies also patients with xanthogranuloma, meningio...

Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes

Sep 13th, 2021 - Type 1 diabetes (T1D) continues to be a disease plagued by hyperglycemia, insulin resistance (IR), and increased cardiovascular disease (CVD) despite advances in insulin delivery and glucose monitoring. Therefore new approaches are needed. Bromocr...

Epidemiology of Pituitary Tumours: Prevalence of Associated Neoplasia

Sep 8th, 2021 - Recent epidemiological studies indicate that clinically relevant PiT have a prevalence around 1%. The Neuromed Scientific Institute for Research and Cure (IRCCS) is a third referral center for the diagnosis and treatment of patients with hypothala...

Validation of a Quality of Life Metric "Prolac-10"

Jun 22nd, 2021 - This is a single-site validation study of a novel quality of life study for patients undergoing medical therapy for prolactinoma. Patients will be consented before starting their medical regimen and complete the "Prolac-10" questionnaire for basel...

see more →

News  13 results

Cabergoline Improves Metabolic Status in Hyperprolactinemia

May 25th, 2022 - Researchers published the study covered in this summary on medRxiv.org as a preprint that has not yet been peer reviewed. Key Takeaways Patients with hyperprolactinemia secondary to a newly diagnosed prolactinoma who received 6 months of treatment...

Avoid pituitary pitfalls in hyperprolactinemia
Heidi Splete

Oct 28th, 2020 - When there is an abnormality in the pituitary gland, many potential areas could be affected because of the extent and range of hormones produced by the “master gland,” Ashlyn Smith, PA-C, of Endocrinology Associates, Scottsdale, Ariz. , said in a p.

Prolactin, the pituitary, and pregnancy: Where’s the balance?
Clinical Endocrinology News;

Apr 26th, 2018 - What if the tumor grows in pregnancy? During pregnancy, high estrogen levels from the placenta can stimulate prolactinoma growth, and the dopamine agonist’s inhibitory effect is gone once that medication’s been stopped. This means that “We have bo.

Woman, 29, With Persistent Migraine
Beth Gundy, PA-C, Laura M. Gunder-Mcclary, DHSC, MHE, PA-C

Feb 1st, 2012 - A 29-year-old woman with a history of frequent migraines presented to her primary care provider for a refill of medication. For the past two years she had been taking rizatriptan 10 mg, but with little relief.

Prolactinoma: A Case Study
Sonia Bahroo, PA-C

Nov 1st, 2011 - A 42-year-old obese woman with type 2 diabetes, diabetic retinopathy, hypertension, and hirsutism presents to discuss an elevated prolactin level of 144. 8 ng/mL (normal range, 4.

see more →

Patient Education  11 results see all →